Mesha Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 32 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.62 Cr
- Revenue Growth 143.81%
- Profit Growth 31.82%
- Ebitda 14.32%
- Net Worth 4.69%
- Total Assets 5.42%
About Mesha Pharma
Mesha Pharma Private Limited (MPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 18 September 1992 and has a history of 32 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.62 Cr.
Parimal Shah and Keyur Shah serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24230MH1992PTC068607
- Company No.
068607
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Sep 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Mesha Pharma Private Limited offer?
Mesha Pharma Private Limited offers a wide range of products and services, including Fatty Esters, Methyl Ester, Chemical Intermediates, Intermediate Chemicals, Cosmetics, Hair & Beauty Products, Cosmetic Raw Material, Organic and Inorganic Solvents, Alcohol Solvents, Dimethyl Sulphate, Ketones.
Who are the key members and board of directors at Mesha Pharma?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Parimal Shah | Whole-Time Director | 30-Mar-1999 | Current |
Keyur Shah | Whole-Time Director | 15-Nov-2002 | Current |
Financial Performance of Mesha Pharma.
Mesha Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 143.81% increase. The company also saw a substantial improvement in profitability, with a 31.82% increase in profit. The company's net worth moved up by a moderate rise of 4.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Mesha Pharma?
In 2023, Mesha Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹16.21 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.87 Cr
- Others : 0.75 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
24 Jun 2022 | Others | ₹7.50 M | Open |
04 Apr 2001 | Bank Of Baroda | ₹8.71 M | Open |
How Many Employees Work at Mesha Pharma?
Unlock and access historical data on people associated with Mesha Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mesha Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mesha Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.